Document is current
Any future updates will be listed below
-
Authors
Teixeira, Luis
Levy, Christelle
Coeffic, David
Ghorbal, Rim
Dupin, Julien
Esposito, Nazario
Derbel, Olfa
-
Funding
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd, Boulogne-Billancourt, France
- License Information
-
More Information
Article History
Received: 11 October 2023
Accepted: 5 June 2024
First Online: 9 January 2025
Declarations
:
: The study received ethical approval from the Independent Ethics Committee (comité de protection des personnes) Sud-Ouest and Outre-Mer IV, Limoges, France and from the French health authorities (Agence nationale de sécurité du médicament et des produits de santé). The study was designed and conducted in accordance with the study protocol, the ethical principles of the “Declaration of Helsinki”, the International Council for Harmonization (ICH) Good Clinical Practice (GCP) guidelines, and applicable laws and regulations. In addition, the study was performed in accordance with current regulations relative to medical devices (ISO 14155: 2011). All patients signed a written informed consent before any procedure related to the study was performed.
: Not applicable.
: The authors declare the following competing interests: LT is an Advisory Board member of AZD, Daiichi, Eisai, Gilead, Invectys, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. CL is an Advisory Board member of AstraZeneca, Daiichi, Lilly, MSD, Novartis, Pfizer, Roche, Seagen. DC is an Advisory Board member of Roche, Pfizer, AstraZeneca, Astellas, GSK. RM, NE, JD are Roche employees. OD is an Advisory Board member of Roche, Pfizer, AstraZeneca, Novartis, GSK, Seagen.
